Intellectual Property India Publishes Patent Application for 'Gabaa Receptor Modulators And Uses Thereof' Filed by Engrail Therapeutics, Inc.

MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517042696 A) filed by Engrail Therapeutics, Inc., San Diego, on May 2, for 'gabaa receptor modulators and uses thereof.'

Inventor(s) include Serrats, Jordi; Vadodaria, Krishna; Vanover, Kimberly; Taylor, Eve; and Cunningham, Stephen.

The application for the patent was published on Aug. 8, under issue no. 32/2025.

According to the abstract released by the Intellectual Property India: "Described herein are uses of 2',6-difluoro-5'-(3-(2-hydroxypropan-2-yl)imidazo[1,2-b][1,2,4]triazin-7-yl)-[1,1'-biphenyl]-2-carbonitrile or a salt thereof. Also described herein are compositions, such as dosage forms, of 2',6-difluoro-5'-(3-(2-hydroxypropan-2-yl)imidazo[1,2-b][1,2,4]triazin-7-yl)-[1,1'-biphenyl]-2-carbonitrile or a salt thereof, and uses thereof."

The patent application was internationally filed on Oct. 03, 2023, under International application No.PCT/US2023/075849.

Disclaimer: Curated by HT Syndication.